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A new flow-adjustable pump for coronary hemoperfusion to
prevent ischemia during routine coronary angioplasty was evalu-
ated in a multicenter prospective study of 110 patients. The
protocol included patients who had angina or ST segment eleva-
tion during a control balloon inflation of ::53 min. Hemoperfusion
was performed by means of a new large lumen angioplasty
catheter utilizing the patient's renal vein or femoral artery blood.
Vessels perfused were the left anterior descending coronary artery
(n =74), right coronary artery (n =39), left circumflex artery
(n =9) and coronary vein grafts (n =15).
Mean (± SD) perfusion flow was 41 ± 9 mllmin (range 17 to
70); mean perfusion time was 9.3 ± 4 min (median 8.5, range 2 to
30). Chest pain score (0 to 4) decreased from 2.9 ± 1 to 1.4 ± 1
during hemoperfusion (p < 0.001); ST segment elevation score (0
to 4) decreased from 2.6 ± 1 to 0.7 ± 1 (p < 0.005) and inflation
time increased from 1.3 ± 0.9 to 7 ± 4 min, (p < 0.001). At least
Balloon inflation during coronary angioplasty causes inter-
ruption of flow and attendant ischemia, the degree of which
depends, among other factors, on the duration of inflation,
vessel size, extent of jeopardized myocardium and presence
of collateral vessels (1). Clinically, during balloon occlusion,
patients may experience angina, ST segment elevation,
arrhythmias and hemodynamic deterioration. Wall motion
abnormalities as detected by intraprocedural two-dimen-
sional echocardiography often precede those clinical mani-
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a 50% increase in tolerated inflation time was obtained in 104
patients (95%). Free plasma hemoglobin and creatine kinase
levels did not increase significantly over baseline values.
Angioplasty was successful in 107 patients (97%), with mean
stenosis reduced from 87 ± 11% to 20 ± 17%; 3 patients had
urgent bypass surgery, 2 (1.8%) had a myocardial infarction (1 Q
wave, 1 non-Q wave) and 2 (1.8%) died later in the hospital of
probable noncoronary causes. Complications related to hemoper-
fusion were transient heart block during dilation of the right
coronary artery in two patients and hematoma requiring transfu-
sion in five (4.5%).
Thus, this initial feasibility study indicates that this new
hemoperfusion system is safe and effective in ameliorating isch-
emia and allowing longer balloon inflations during coronary
angioplasty.
(1 Am Coll CardioI1992;19:657-62)
festations (2,3). Although clinical ischemia is usually revers-
ible on balloon deflation and restitution of flow (especially
with occlusions of very short duration), balloon inflation
may be poorly tolerated in many patients, a factor that may
significantly limit the performance of effective dilation.
Since the first clinical application of coronary angio-
plasty, reduction or prevention of intraprocedural ischemia
has been the object of intense investigation. Techniques
devised to achieve this goal include passive autoperfusion
catheters (4,5), active oxygen carrier perfusion (6) and
coronary sinus retroperfusion (7). Active hemoperfusion
systems, consisting of manual or roller pumps, have also
been used (8-11) with variable but encouraging results. In
this multicenter study, we prospectively evaluated the safety
of a newly designed, flow-adjustable, active hemoperfusion
pump and its effectiveness in ameliorating ischemia during
routine coronary angioplasty.
Methods
Patient characteristics (Table 1). From August 1988 to
November 1990, 110 patients were enrolled in the study.
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CABG : coronary artery bypass surgery; CAD : coronary artery
disease; FC : Canadian Cardiovascular Society functional class; MI :
myocardial infarction; PlCA : coronary angioplasty.
There were 86 men and 24 women with a mean age of 60 ±
12 years; 49 patients (45%) had a previous myocardial
infarction, 16 (14%) prior bypass surgery, 23 (21%) prior
angioplasty; 62 patients (57%) had unstable angina and 39
(35%) were in Canadian Cardiovascular Society functional
class III and 55 (50%) in functional class IV. Single-vessel
disease was present in 65 patients (60%) and multivessel
disease in 45 (40%); 80 patients (73%) had single-vessel
angioplasty, 30 (27%) had multivessel angioplasty; multiple
vessels were perfused in 17 patients (15%). A total of 121
lesions were dilated; of these, 54 were proximally located (0
to 5 em from the coronary ostium), 59 were located 5 to
to em from the origin and 8 were distally located (> to em
from the ostium). Lesion characteristics were as follows: 21
(17%) were calcific, 87 (72%) were eccentric, 99 (82%) were
> to-mm long and 9 (7%) had intraluminal thrombi before
angioplasty. However, lesion morphology was not a selec-
tion criterion for hemoperfusion.
Pump characteristics. The hemoperfusion system con-
sists of a battery-operated portable pump (Corflo, Leocor,
Inc.) with a large lumen over the wire balloon catheter (Fig.
1) designed to infuse the patient's own blood into the distal
coronary artery during angioplasty. The pump is smaller
than a shoe box and weighs approximately 3.2 kg; the
battery provides 90 min of operation and is rechargeable.
The pump has two components: a reusable nonsterile driver
and a sterile disposable head, consisting of an inlet tubing, an
intake valve, a piston pump, an outlet valve, an outlet
pressure accumulator that transforms cyclic flow in a semi-
continuous flow pattern and an outlet tubing.
The balloon catheter is made by the same manufacturer
and is characterized by a standard over the wire design, with
thin nylon walls, a large proximal inner lumen (0.032 in.
[0.081 em]) and tapered distal tip (deflated balloon profile
0.033 to 0.035 in. [0.084 to 0.89 em]). The pump head is
initially primed with saline solution and purged of air bubbles
and then easily fit over the driver. On crossing the lesion
with the balloon, the guide wire is removed and the inflow
and outflow tubings of the sterile head are connected to the
patient's blood source and the distal port of the balloon
catheter, respectively. The driver's control panel allows the
Table 1. Clinical Characteristics of 110 Patients
Age (yr)
Men
Prior MI
Prior CABG
Prior PlCA
Unstable angina
FC III
FC IV
Single-vessel CAD
Multivessel CAD
60 ± 12
86 (78%)
49 (45%)
16 (14%)
23 (21%)
62 (57%)
39 (35%)
55 (50%)
65 (60%)
45 (40%)
Figure l. Corflo hemoperfusion pump with the sterile, disposable
head with inflow and outflow connections (top) and the portable
reusable driver with control panel (bottom).
operator to adjust the flow rate (in ml/min). The pump can
generate pressures up to 200 psi and deliver flow up to
80 ml/min through the balloon catheter.
Study protocol. The study group included patients who
underwent elective coronary angioplasty and signed in-
formed consent approved by the respective Institutional
Review Boards of the participating centers.
A control routine balloon inflation without perfusion was
performed initially. If this caused ST segment elevation or
chest pain, or both, before 3 min, the patient was enrolled in
the study and hemoperfusion was performed with the sub-
sequent balloon inflations. The end point was to assess the
lessening of ischemia and to prolong inflation time by ~50%
of the control duration; in general, operators aimed at a
"perfused" inflation time of ~5 min.
Exclusion criteria were: I) evolving myocardial infarc-
tion; 2) severe sequential lesions in the vessel that may
have precluded distal perfusion; 3) a large side branch
originating from the stenotic segment; 4) vessel size <2 mm;
and 5) absence of angina and ST segment elevation during
the control inflation. Patients selected for the study usually
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Figure 2. Significant decrease in scores for chest pain and ST
segment elevation during hemoperfusion (Pert) (see text). EeG =
electrocardiographic; Pre = before balloon inflation.
50% of cases; however, no differences in hemoperfusion
results were noted between this source and arterial blood
(mean oxygen saturation 98%). Mean perfusion flow was
41 ± 9 mllmin (range 17 to 70) for all vessels; mean perfusion
time was 9.3 ± 4 min (range 2 to 30, median 8.5). Perfusion
data by vessel are reported in Table 2 and Figure 4.
Mean creatine kinase levels obtained before the proce-
dure and 6 and 12 h after angioplasty were 64, 80 and
156 mg/dl. respectively. The mean plasma free hemoglobin
was 5.5 mg/dl (normal 1 to 4) after perfusion. There was no
clinically detectable hemoglobinuria.
Because of technical problems, hemoperfusion could not
be instituted in three patients; all three were excluded from
further evaluation.
Angioplasty results (Table 3). Coronary angioplasty was
successful in 107 (97%) of the 110 patients and 117 (97%) of
had a proximal lesion in large vessels supplying viable
myocardium, considered to be a potential cause of severe
ischemia during balloon inflation.
Chest pain and ST elevation were monitored and re-
corded by a trained nurse before, after and every minute
during balloon inflation; both were scored on a scale of 0 to
4 as follows: ST elevation (on a 12-lead electrocardiogram
[ECG)): 0 = no change; 1 = ~1-mm elevation; 2 = ~2-mm
elevation; 3 = ~3-mm elevation; 4 = :::::3-mm elevation.
Chest pain was subjectively graded on a scale of 0 to 10 by
the patients and scored as: 0 = no pain; 1 = minimal pain (1
to 3/10); 2 =moderate (4 to 6/10); 3 = severe (7 to 9/10); 4 =
very severe (10/10).
Perfusion procedure. Patients were given a bolus injec-
tion of 15,000 to 20,000 U of heparin after arterial access.
Autologous blood was obtained according to operator pref-
erence from the contralateral femoral artery, the side arm of
the arterial sheath used for the angioplasty procedure or the
renal vein (owing to the usually high oxygen saturation of
renal vein blood) and infused through the distal port of the
balloon catheter. However, renal vein blood was not utilized
when its oxygen saturation was <80% despite oxygen ad-
ministration by nasal cannula. Pump flow was set initially at
30 to 40 mllmin according to vessel size and distribution and
gradually increased to 70 mllmin, with the goal to suppress
ischemic manifestations. During the procedure, activated
clotting time was monitored and maintained>300 s. Serum
creatine kinase levels were obtained before and 6 and 12 h
after angioplasty; free plasma hemoglobin was obtained at
the end of the procedure from a systemic blood sample, as a
measure of hemolysis.
Statistical analysis. Procedural information, angiographic
and clinical data up to the patient's discharge were recorded
on data forms and analyzed by a central monitoring labora-
tory. The chi-square test was used to compare discrete
variables and the t test to compare continuous variables.
Values are expressed as mean values ± SD.
4
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Figure 3. Significant increase in balloon inflation time during he-
moperfusion (Pert) (see text). Other abbreviation as in Figure 2.Results
Perfusion data. Coronary vessels treated were the left
anterior descending coronary artery (n = 74), left circumflex
artery and its branches (n = 9), right coronary artery (n =
39), coronary vein grafts (n = 15). The mean duration of the
initial nonperfused control balloon inflation was 1.3 ±
0.9 min (range 0.16 to 3), during which patients developed a
chest pain score of 2.9 ± 1 and an ST segment elevation
score of 2.6 ± 1 (Fig. 2). With hemoperfusion, the duration
of balloon inflation increased to 7 ± 4.4 min (range I to 30,
median 5.25) (p < 0.001) (Fig. 3). A :::::50% increase in
tolerated inflation time was observed in 105 patients (95%).
The chest pain score decreased to 1.4 ± 1(p < 0.001) and the
ST segment elevation score to 0.7 ± 1, (p < 0.05). Two
patients had persistent chest pain due to temporary occlu-
sion of a side branch during balloon inflation. Renal vein
blood with a mean oxygen saturation of 89% was utilized in
8 5.0.:4.4
Pre Perf
INFLATION TIME
660 DISCIASCIO ET AL.
NEW HEMOPERFUSION PUMP FOR ANGIOPLASTY
JACC Vol. 19. No.3
March I. 1992:657-62
Table 2. Perfusion Data by Coronary Vessel Table 3. Angioplasty Results in llO Patients
Pre Perl Pre Perl Pre Perl Pre Perl
LAD RCA LCX Grafts
Figure 4. Significant increase in balloon inflation time by individual
vessel (see tex!>. LAD = left anterior descending coronary artery;
LCX = left CIrcumflex coronary artery; RCA = right coronary
artery; other abbreviations as in Figure 2.
LAD 74 43 (17-70) 9.4
RCA 39 39 (17-70) 9.3
LCx 9 36 (22-50) 7.9
Grafts 15 41 (25-60) 8.3
LAD = left anterior descending artery; LCx = left circumflex artery;
Perf = perfusion; RCA = right coronary artery.
2 (1.8%)
3 (2.7%)
2(1.8%)
2 (1.8%)
5 (4.5%)
3 (2.7%)
107 (97%)
87 ± II
20 ± 17
Angiographic success
% stenosis, pre
% stenosis, post
Complications
Urgent CABG
MI
(I Q wave, I non-Q wave)
Death
Hemoperfusion related
Complete heart block
Entry site hematoma
Technical problems
Discussion
Available perfusion systems. The importance of myocar-
dial protection during angioplasty is well recognized and
several perfusion systems are now being investigated or are
post and pre = after and before angioplasty, respectively; other abbrevi-
ations as in Table I.
vessel; the latter lesion was subsequently dilated during a
second procedure.
Repeat angioplasty was performed 6 days after the initial
procedure in one patient because of a return of chest pain
and angiographic evidence of partial restenosis.
Two patients died. The first was an 84-year old man with
severe left ventricular dysfunction (ejection fraction 20%)
who underwent angioplasty of a left anterior descending
graft and distal native vessel because of unstable angina and
congestive heart failure. He had asystole 48 h later while
straining in the bathroom, but recovered with temporary
cardiac pacing; however, the patient had a second episode of
asystole 2 days later, accompanied by pacemaker malfunc-
tion, and died. He had no angina or evidence of infarction
after the first asystolic episode. The second patient who died
had abrupt reclosure (accompanied by chest pain) of a large
left circumflex artery 48 h after angioplasty, which was
successfully redilated without evidence of infarction. How-
eve~, 2 days later, he died suddenly without preceding
angma. No postmortem examination could be obtained in
either patient.
In total, the incidence of urgent bypass surgery was 2.7%
(3 of 110), myocardial infarction 1.8% (2 of 110) and death
1.8% (2 of 110). Overall, five patients (4.5%) had a least one
major complication during the hospital stay attributable to
the angioplasty procedure.
Complications related to hemoperfusion. Two patients
(1.8%) had transient complete heart block during dilation of
~he rig?t coronary artery; this was not accompanied by
IschemiC ECG changes or local hyperkalemia and was
reversed by discontinuation of hemoperfusion. Five patients
(4.5%) developed entry site hematoma requiring transfusion;
one patient had mild transient exacerbation of preexisting
chronic renal failure, probably dye-induced.
Perf Time
(min)
Flow Rate
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7
c
,g3
!i
'E-2
o
8
the 121 lesions, with mean stenosis reduced from 87 ± 11%
to 20 ± 17% (p < 0.001). The Leocor balloon was used as a
primary dilating catheter in all except two cases that re-
quired predilation with a smaller profile balloon because of
the rigidity of the lesion (one case) or distal location (one
case). The majority of the vessels (80%) were dilated with a
3- or 3.5-mm balloon and 20% with a 2.5-mm balloon.
Complications. Complications related to the balloon pro-
cedure were as follows. Three patients (2.7%) underwent
urgent bypass surgery after failed angioplasty; two of them
were transferred to the operating room with ongoing hemo-
perfusion, which was maintained for approximately 1 h in
one (until cardiopulmonary bypass was initiated). This pa-
tient's left ventricular ejection fraction improved postoper-
atively from 20% to 50%. Only one of the three patients
undergoing urgent surgery had a small non-Q wave infarc-
tion (creatine kinase less than twice normal values).
Two additional patients had a myocardial infarction; one
of them had abrupt reclosure 24 h after angioplasty on
discontinuation of heparin. The vessel was successfully
redilated and the patient developed a non-Q wave infarction.
Another patient had a non-Q wave infarction after angio-
plasty as a result of ischemia produced by an untreated
JACC Vol. 19, No.3
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available in clinical practice to provide support during the
procedure. Meier et al. (8) tested a roller pump for distal
coronary perfusion in 11 dogs, utilizing arterial autologous
blood; however, 5 dogs died because of system thrombosis
or failure. Subsequently, Heibig et al. (10) obtained satisfac-
tory results with a lessening of ischemia and prolongation of
balloon inflation during coronary angioplasty in 17 patients,
utilizing two commercially available roller pumps (the Olson
coronary perfusion pump and the Shiley-Stocker low flow
pump) or angiographic power injectors. Unlike the roller
pump, the piston mechanism was able to generate pressures
to maintain adequate flow through the inner lumen of the
balloon catheter; however, its limitation was the capacity of
the injector (150 m1).
Technical aspects. The present hemoperfusion pump has
several technical advantages over the previous devices. It
functions with a piston mechanism and is able to deliver
adjustable and reliable flow rates :::;80 ml/min in a semicon-
tinuous pattern, which can be maintained for 90 min with a
single battery that can be changed in few seconds. It can
generate pressures up to 200 to 220 psi with an overload
mechanism that turns the system off automatically. This
device is potentially more attractive than commercially
available passive autoperfusion catheters (4,5), which by
design are aortic pressure-driven and thus deliver a nonad-
justable, unmeasured and probably lower flow to the distal
coronary bed. Conversely, active distal perfusion with an
oxygen carrier (Fluosol) (6) can be performed at controlled
rates by an angiographic injector; however, potentiallimita-
tions include cumbersome preparation, cost and incomplete
myocardial protection as compared with blood perfusion
(12).
Coronary sinus retroperjusion is still under investigation
(7), but preliminary data failed to show reliable myocardial
protection during angioplasty of vessels other than the left
anterior descending coronary artery (13).
Other systems such as percutaneous cardiopulmonary
bypass, although proved to be as reliable as systemic hemo-
dynamic support (14), do not supply direct myocardial
protection and are limited by cost and significant morbidity.
Immediate results: safety. This study indicates that this
new hemoperfusion system can be safely employed during
routine coronary angioplasty without significant complica-
tions. The occurrence of complete heart block in two cases
of right coronary hemoperfusion appeared to be related not
to ischemia but to reflex stimulation of the vessel wall by the
jet flow; this finding may warrant prophylactic temporary
pacemaker insertion during angioplasty of the right coronary
artery.
Although no thromboembolic complications were de-
tected, the higher heparin dose given during the procedure
may be responsible for the 4.5% incidence rate of entry site
hematomas requiring transfusion, which appears to be
greater than that observed with routine angioplasty (15).
Delayed withdrawal of the vascular sheaths with strict
monitoring of coagulation variables is therefore warranted.
Hemolysis was negligible as indicated by free hemoglobin
levels and absence of hemoglobinuria.
Finally, the three cases of pump technical failure were
due to air bubbles in the system caused by faulty intake
valves in the disposable head. This technical problem was
detected during priming of the device and before the hemo-
perfusion procedure, which was therefore not performed; it
has since been corrected by the manufacturer.
Ischemia protection. This study demonstrates that this
distal hemoperfusion technique is effective in ameliorating
ischemia during coronary angioplasty. The reduction of both
ST segment elevation and chest pain scores was significant;
this not only facilitates the procedure by increasing the
patient's and the operator's comfort, but may be extremely
useful in patients with extensive areas of myocardium at
jeopardy (such as those undergoing dilation of the only
remaining vessel), patients with left ventricular dysfunction,
patients with ongoing refractory ischemia, and high risk
cases in general.
The protocol did not include a systematic analysis of
intraprocedural wall motion abnormalities and therefore
those data are not included in this study. However, a
prospective investigation to evaluate an improvement or
reversal of balloon occlusion-induced wall motion abnormal-
ities by this method may be warranted.
Echocardiographic evidence of segmental left ventricular
dysfunction persisting after balloon deflation (3) persuaded
some investigators in this study to prolong perfusion after
full deflation of the balloon was achieved; hence, the longer
perfusion versus inflation times in our study.
It is of note that in two patients who had intractable
abrupt reclosure requiring emergency bypass surgery, he-
moperfusion provided effective ischemia protection during
transport to the operating room; neither of these patients had
myocardial infarction. However, in these two patients, he-
moperfusion was not instituted as a "bailout" technique
after the complication ensued, but was immediately avail-
able because the patients were already enrolled in the study.
Nevertheless, because of its ease of preparation and assem-
bly (which takes an average of 5 min), it is conceivable that
this pump may also be an effective standby support device
for failed angioplasty.
In two patients, the protection from ischemia was incom-
plete because of side branch occlusion during inflation,
which led to persistent chest pain despite "adequate" per-
fusion. This problem, which is also observed with autoper-
fusion catheters (5), can sometimes be obviated with careful
positioning of the balloon; a double ("kissing") balloon
perfusion system may even be envisioned in extreme cases.
Finally, although a preconditioning effect that would allow
better tolerance of ischemia at subsequent inflations ("fading
ischemia") has been described (16), other studies (2) found
no difference in time to onset of ischemia during repeated
balloon inflations.
Prolongation of inflation. Reduction of ischemia with this
method allowed a more than fivefold prolongation of infla-
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tion times, with 95% of the patients having a ;:::50% increase
in tolerated balloon inflation time. However, the role of long
inflations in improving balloon angioplasty outcome is still to
be defined. Inflations of long duration may be beneficial in
improving acute angiographic results (17), presumably by
more stable "molding" of the vessel architecture, and have
been used to seal dissections threatening abrupt reclosure
(18). Furthermore, considerable interest exists concerning
the potential impact of long inflations on restenosis rate (19)
and this will warrant further investigation.
Conclusions. This new, flow-adjustable, active antero-
grade hemoperfusion pump is a reliable and simple device to
perfuse the distal coronary artery bed during angioplasty. It
appears to be safe and effective in both reducing ischemia
and prolonging balloon inflation time and compares favor-
ably with other perfusion systems currently available (20).
The full spectrum of its applications needs to be further
investigated in a wide range of patient subgroups.
Appendix
CHIPS Participating Centers
Medical CoUege of Virginia, Richmond, Virginia: Principal Investigator, G.
DiSciascio; Coinvestigators, M. J. Cowley, E. Goudreau.
Texas Heart Institute, St. Luke's Episcopal Hospital, Houston, Texas:
Principal Investigator, R. Leachman; Coinvestigators, A. Massumi, P. Ange-
lini.
St. Louis University, St. Louis, Missouri: Principal Investigator, M.
Vandormael; Coinvestigator, H. Serota.
Johns Hopkins University, Baltimore, Maryland: Principal Investigator, J.
Brinker; Coinvestigator, H. Grill.
University of Alabama, Birmingham, Alabama: Principal Investigator, L.
Dean; Coinvestigators, G. Roubin, W. Baxley.
Emory University School of Medicine, Atlanta, Georgia: Principal
Investigator, N. Lembo; Coinvestigator, J. Douglas.
Veterans Administration Hospital, Houston, Texas: Principal Investigator,
J. Heibig.
Humana Hospital, Orlando, Florida: Principal Investigator, G. Andreae.
Methodist Hospital, Lubbock, Texas: Principal Investigator, M. Seger.
Spohn Hospital, Corpus Christi, Texas: Principal Investigator, C.
Schechter; Coinvestigator, R. Graf.
Southwest Texas Methodist Hospital, San Antonio, Texas: Principal Inves-
tigator. R. N. Schnitlzer.
The General Hospital Center at Passaic, New Jersey: Principal Investigator,
P. Rossi.
St. Joseph's Hospital Health Center, Syracuse, New York: Principal Inves-
tigator, A. Gianbartolomei; Coinvestigators, P. Esente, L. Johnson.
Scott and White Memorial Hospital, Temple, Texas: Principal Investigator,
L. Watson.
Data Coordinating Center: Principal Investigator, P. Angelini; Coinvesti-
gators, G. DiSciascio, R. Snyder.
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